Médecine

Paramédical

Autres domaines


S'abonner

Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States - 16/05/19

Doi : 10.1016/j.jaad.2019.01.039 
Steven R. Feldman, MD, PhD a, Stephane A. Regnier, PhD b, , Alexandra Chirilov, BS c, Felix Hey, BA d, Isabelle Gilloteau, MSc b, David Cella, PhD e
a Department of Dermatology, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina 
b Novartis AG, Basel, Switzerland 
c GfK SE, Nuremberg, Germany 
d Ipsos SA, Nuremberg, Germany 
e Department of Medical Social Sciences, Northwestern University, Chicago, Illinois 

Correspondence: Stephane A. Regnier, PhD, Novartis Campus, CH-4056 Basel, Switzerland.Novartis CampusBaselCH-4056Switzerland

Abstract

Background

Psoriasis Area and Severity Index (PASI) response rates have been the benchmark for evaluating treatment efficacy in trials involving moderate-to-severe psoriasis.

Objective

To understand how dermatologists assess biologics and which trade-off rules they apply when planning psoriasis treatment.

Methods

Two online surveys of 130 and 129 US dermatologists (surveys 1 and 2, respectively) were conducted with use of direct and indirect elicitation via discrete choice experiment. Respondents were asked to choose hypothetical biologics on the basis of 6 attributes (a ≥75% reduction from baseline in PASI score or a ≥90% reduction from baseline in PASI score, infection risk, dosing frequency, and 3 patient-reported outcomes [PROs] [relief of depression, relief of itching, and impact on usual activities]).

Results

Most dermatologists (74% in survey 1 and 76% in survey 2) reported using both PASI and PROs when selecting a biologic. PASI response rate was the most important attribute (35%-38% of overall decision weight), whereas combined PRO attributes had similar importance (36% of decision weight). Infection risk and dosing frequency influenced the decision to a lesser extent.

Limitations

Potential bias in considering 3 PROs versus 1 PASI rate and 1 safety attribute.

Conclusion

PASI is most important for dermatologists selecting biologics, but PROs are also considered, especially when PASI response rate is similar between treatments. PRO data should be collected in trials involving moderate-to-severe psoriasis.

Le texte complet de cet article est disponible en PDF.

Key words : biologics, patient-reported outcomes, psoriasis, Psoriasis Area and Severity Index, treatment decision making

Abbreviations used : HRQoL, PASI, PASI 75, PASI 90, PRO, SoP


Plan


 Funding sources: Supported by Novartis AG.
 Disclosure: Dr Feldman has received research, speaking, and/or consulting support from Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Ortho Dermatology, AbbVie, Samsung, Janssen, Eli Lilly and Company, Merck, Novartis, and Sun Pharma. Dr Regnier and Ms. Gilloteau are employees of and own stock in Novartis AG. Ms Chirilov and Mr Hey are employees of GfK SE and Ipsos SA, respectively, which received funding for this study from Novartis. Dr Cella has received consulting honoraria from Novartis and research grants to his institution from Novartis.
 Reprints not available from the authors.


© 2019  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 80 - N° 6

P. 1650-1657 - juin 2019 Retour au numéro
Article précédent Article précédent
  • Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment
  • Makenzie L. Hawkins, Matthew J. Rioth, Megan M. Eguchi, Myles Cockburn
| Article suivant Article suivant
  • Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013
  • Anagha Bangalore Kumar, Elizabeth K. Blixt, Lisa A. Drage, Rokea A. el-Azhary, David A. Wetter

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.